Market Eyes LiveCME Group Inc. (CME) Stock Rating & Analysis
MELANY's data-driven read on CME Group Inc. · Security & Commodity Brokers, Dealers, Exchanges & Services.
CME Group, based in Chicago, operates exchanges where investors, suppliers, and businesses trade futures and derivatives tied to interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and completed its IPO in 2002, after which CME Group merged with rival CBOT Holdings in 2007 and acquired Nymex Holdings in 2008 and NEX in 2018.
Why CME scores 50/100
MELANY scores CME Group Inc. 50/100 by weighing eight factors. Here is how CME breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 100%
Direction and relative strength of the recent share-price trend.
- Price +8.1% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for CME
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
CME Group Inc. sits in the Financials / rate cycle theme, which MELANY currently rates 45/100 for strength. Theme strength feeds CME's momentum and catalyst factors above.
Tracking CME
CME Group Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add CME to your watchlist and get alerted the moment the rating changes.
How MELANY rates CME
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. CME Group Inc.'s 50/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CME
Is CME Group Inc. (CME) a buy?
As of 2026-08-20, MELANY rated CME Group Inc. Hold with a composite score of 50/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is CME Group Inc.'s MELANY score?
CME Group Inc. (CME) has a MELANY composite score of 50/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the CME stock rating calculated?
MELANY scores CME from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy CME Group Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates CME Group Inc. (CME) Hold with a composite of 50/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CME stock price forecast?
MELANY does not publish price targets or forecasts for CME. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 50/100 across eight factors for CME Group Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CME stock overvalued or undervalued?
MELANY's valuation factor currently reads 23/100 for CME Group Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CME's read.
What price should I buy CME at?
MELANY is not flagging a fresh entry for CME at its current Hold rating, so there is no entry zone to publish right now. Watchlisting CME in the free app gets you alerted the moment that changes.
What are the risks of buying CME stock?
The top risks MELANY currently flags for CME Group Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is CME Group Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 84/100 for CME Group Inc., and earnings track record, at 58/100. The 50/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CME stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 44/100 for CME right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CME rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CME continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
CME's live rating and alerts are free either way. The app is our flagship.